NEW YORK CITY, NY / ACCESS Newswire / March 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...

The UK MHRA has validated Bavarian Nordics’ marketing authorisation application for its single-dose chikungunya vaccine.

“Restricting language tied to race, gender, and equity could impair the ability of researchers to analyze disparities in ...

The global attenuated vaccines market is set for remarkable expansion, with sales projected to surge from USD 5,068.2 million in 2024 to an estimated USD 9,693.9 million by 2034. This growth ...

In a phase 1 trial, patients with pancreatic ductal adenocarcinoma who were treated with surgery and bespoke neoantigen mRNA vaccines combined with anti-PD-L1 and chemotherapy exhibited marked ...

From a historic vaccine approval to a $50bn investment reshaping US drug manufacturing, February brought major pharma news to ...

On February 25, 2025, the U.S. Centers for disease Control and Prevention ("CDC") posted a notice on its website announcing that "CDC is currently investigating five hospitalizations for cardiac or ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United States and Europe ...

HC Wainwright reaffirmed their buy rating on shares of Valneva (NASDAQ:VALN – Free Report) in a report published on Friday morning,Benzinga reports. HC Wainwright currently has a $17.00 price ...

If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025 – ...

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus ... Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, said, “Given the substantial risk that ...